Brief: Madrigal Pharmaceuticals Q3 EPS USD -5.08
04/11/2025 12:00
Nov 04 (Reuters) - Madrigal Pharmaceuticals Q3 net income USD -114.19 million. Q3 operating expenses USD 401.243 million Q3 operating income USD -113.975 million Q3 product revenue USD 287.268 million
Recent news on Madrigal Pharmaceuticals
See all newsBrief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand
U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPal
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)